FibroBiologics has been granted a US patent for a novel method leveraging fibroblasts to improve the survival and function of transplanted pancreatic islets, boosting prospects for advanced type 1 diabetes therapies and beyond.
FibroBiologics said it has been granted a US patent for a method designed to improve pancreatic islet transplantation, a potential step forward in treating type 1 diabetes. The patent covers the use of fibroblasts to help transplanted islets take hold more effectively and function better, addressing one of the main obstacles that has long limited the therapy’s wider use.
According to the company, the approach is intended to create a more supportive environment for the transplanted cells, which can struggle to survive after implantation. FibroBiologics said that could improve viability and performance, and may also have implications beyond diabetes, including other cell and tissue transplant applications.
The latest patent sits within a broader intellectual property push from the clinical-stage biotechnology group, which says it now has more than 270 issued and pending patents across several development areas. Recent filings and announcements show the company is also pursuing oral delivery systems for fibroblast-based therapeutics, cartilage regeneration methods and manufacturing work tied to its diabetic foot ulcer programme.
That wider pipeline suggests FibroBiologics is trying to build a platform around fibroblasts rather than a single product. In earlier disclosures, the company said it had seen preliminary proof of concept for a fibroblast-based pancreatic beta cell spheroid that secreted insulin in laboratory tests, while also moving ahead with manufacturing for CYWC628, its investigational therapy for diabetic foot ulcers.
For investors, the patent grant strengthens the company’s claims around proprietary technology, but the commercial and clinical value will depend on whether the science translates into durable treatment results. Islet transplantation remains a technically difficult field, and the key challenge has always been whether transplanted cells can survive long enough to deliver meaningful benefit.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
